Mechanism or Mode of Action of Antibiotics (Antibacterial Agents)

Antibiotics represent a cornerstone of modern antimicrobial therapy, distinguished by their capacity to interfere with essential biological processes in susceptible bacteria. Their therapeutic effectiveness arises from interactions between specific drug molecules and bacterial structures, enzymes, ribosomal complexes, or metabolic pathways. These interactions disrupt the physiological activities required for bacterial survival, multiplication, and persistence. The mechanism of action of an antibiotic therefore constitutes a fundamental determinant of its antibacterial potency, spectrum of activity, therapeutic application, and potential to select for antimicrobial resistance.

The antibacterial action of antibiotics is governed by the structural and biochemical characteristics of bacterial cells. Unlike human cells, bacteria possess distinctive features, including peptidoglycan-containing cell walls, prokaryotic ribosomes, bacterial DNA replication machinery, and metabolic pathways that differ substantially from those of mammalian tissues. These differences create opportunities for selective toxicity, allowing antimicrobial agents to inhibit microbial functions while comparatively sparing host cellular processes. Selectivity is not absolute, and the pharmacological properties of individual agents influence their safety, distribution, and therapeutic usefulness.

Antibiotics act through several principal molecular targets. Cell wall synthesis inhibitors, including penicillins, cephalosporins, carbapenems, and glycopeptides, interfere with the construction or cross-linking of peptidoglycan, weakening the bacterial envelope and potentially promoting cell lysis. Membrane-active agents, such as polymyxins and daptomycin, compromise membrane integrity or function, disturbing essential processes associated with cellular homeostasis. Protein synthesis inhibitors target bacterial ribosomes, particularly their 30S or 50S subunits. Aminoglycosides, tetracyclines, macrolides, and oxazolidinones interfere with different stages of translation, restricting the production of proteins necessary for bacterial growth and survival.

Other antibacterial agents target the maintenance and expression of genetic information. Fluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV, thereby disrupting DNA replication and chromosome segregation. Rifampicin inhibits bacterial DNA-dependent RNA polymerase, suppressing transcription and subsequent RNA production. Additional compounds interfere with essential metabolic reactions. Sulfonamides inhibit dihydropteroate synthase, whereas trimethoprim inhibits dihydrofolate reductase; both actions impair folate metabolism and consequently restrict the synthesis of nucleotides required for bacterial growth. These distinct mechanisms demonstrate that antibacterial activity can emerge from the interruption of structural assembly, membrane function, genetic processing, or metabolic supply.

The consequences of antibiotic exposure depend on the relationship between the targeted process and bacterial viability. Bactericidal agents produce bacterial killing under appropriate conditions, whereas bacteriostatic agents primarily inhibit bacterial multiplication. This distinction is influenced by the antibiotic, microorganism, concentration, and experimental environment rather than representing an invariably fixed property. Antibacterial effectiveness depends on drug penetration, target accessibility, binding affinity, exposure duration, and the physiological state of the bacterial population. Differences in these factors help explain why organisms may exhibit distinct susceptibility profiles despite sharing broadly similar cellular structures.

The emergence of antimicrobial resistance further emphasizes the importance of understanding antibiotic mechanisms at the molecular level. Bacteria can reduce susceptibility through drug-inactivating enzymes, target modification, decreased membrane permeability, active efflux, and alternative metabolic pathways. Such adaptations may diminish target engagement or prevent intracellular antibiotic concentrations from reaching effective levels. The mechanism of action must be considered alongside resistance determinants, pharmacodynamic characteristics, and the biological context of infection. A precise understanding of antibacterial mechanisms supports rational antimicrobial selection, interpretation of susceptibility testing, development of new therapeutic compounds, and the responsible use of existing antibiotics in clinical practice.

Key antibiotic targets and their effects

Antibiotics are antimicrobial agents that inhibit bacterial growth or cause bacterial death by targeting essential cellular structures and biochemical processes. Their mechanisms of action include inhibition of cell wall synthesis, disruption of cell membrane integrity, inhibition of protein synthesis, interference with DNA replication, suppression of RNA synthesis, and blockade of essential metabolic pathways (Figure 1). Cell wall synthesis inhibitors, such as penicillins, cephalosporins, carbapenems, vancomycin, and fosfomycin, interfere with peptidoglycan formation and weaken the bacterial cell wall, potentially causing cell lysis and death.

Cell membrane-targeting agents, including polymyxins such as colistin and daptomycin, disrupt membrane integrity or cause membrane depolarization, impairing essential cellular functions and leading to bacterial death. Protein synthesis inhibitors act on bacterial ribosomes, which consist of 30S and 50S subunits. Aminoglycosides, such as gentamicin, and tetracyclines, such as doxycycline, target the 30S subunit, whereas macrolides, including azithromycin, chloramphenicol, and linezolid, interfere with protein synthesis through different interactions with the 50S subunit.

These effects prevent bacteria from producing proteins required for growth, reproduction, and survival. DNA replication inhibitors, particularly fluoroquinolones such as ciprofloxacin and levofloxacin, inhibit DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and promoting cell death. RNA synthesis inhibitors, including rifampicin and fidaxomicin, target bacterial RNA polymerase, blocking transcription and disrupting RNA production. Another important mechanism involves inhibition of folate metabolism, which is essential for nucleotide synthesis and bacterial growth.

Sulfonamides inhibit dihydropteroate synthase, while trimethoprim inhibits dihydrofolate reductase, thereby limiting folate availability and DNA synthesis. Additionally, metronidazole damages DNA in susceptible anaerobic bacteria, interfering with genetic functions and causing cell death. These diverse mechanisms explain the therapeutic activity of antibacterial agents and highlight the importance of selecting appropriate antibiotics according to the causative microorganism, susceptibility profile, and potential resistance mechanisms.

Inhibition of microbial cell wall synthesis

The bacterial cell wall is an essential structural barrier that preserves cellular morphology, provides mechanical stability, and protects bacteria against osmotic stress. Peptidoglycan, a mesh-like polymer composed of alternating N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) residues interconnected by short peptide chains, constitutes the principal framework of the cell wall. Although peptidoglycan occurs in virtually all bacteria, its thickness and organization differ considerably between Gram-positive and Gram-negative organisms. Gram-positive bacteria generally possess a thick, multilayered peptidoglycan structure, whereas Gram-negative bacteria have a thinner peptidoglycan layer situated within the periplasmic space between the inner and outer membranes.

Disruption of peptidoglycan biosynthesis compromises the structural integrity of the bacterial envelope. When cell wall assembly is impaired, growing bacteria become vulnerable to osmotic imbalance, which may culminate in cellular swelling and lysis. This vulnerability provides an important therapeutic opportunity because mammalian cells lack peptidoglycan and therefore do not possess the bacterial cell wall machinery targeted by these antibiotics. Cell wall inhibitors can demonstrate substantial selective toxicity, although their clinical effectiveness depends on drug penetration, bacterial susceptibility, and the physiological state of the organism.

Several antibacterial agents interfere with different stages of cell wall construction. These include beta-lactams, such as penicillins and cephalosporins; glycopeptides, including vancomycin; bacitracin; and fosfomycin. Despite sharing a common cellular target system, these agents act through distinct biochemical mechanisms. Beta-lactam antibiotics primarily inhibit the final stages of peptidoglycan assembly by binding to penicillin-binding proteins (PBPs), particularly the transpeptidases responsible for cross-linking adjacent peptide chains.

This cross-linking reaction strengthens the peptidoglycan network and enables the cell wall to withstand internal osmotic pressure. By acylating susceptible PBPs, beta-lactams prevent effective transpeptidation, resulting in defective cell wall formation and weakening of the bacterial envelope. In susceptible, actively growing bacteria, this disruption can trigger autolytic processes and lead to cell death. The antibacterial effect is therefore associated with inhibition of peptide cross-linking rather than direct prevention of the initial linkage between NAG and NAM sugar residues.

Other cell wall inhibitors act at different stages of peptidoglycan synthesis. Vancomycin and related glycopeptides bind to the D-alanyl-D-alanine termini of peptidoglycan precursors, obstructing their incorporation into the growing cell wall. Bacitracin interferes with the recycling of bactoprenol, a lipid carrier required to transport peptidoglycan precursors across the cytoplasmic membrane. Fosfomycin inhibits MurA, an enzyme involved in the initial cytoplasmic stages of peptidoglycan precursor synthesis. These differences illustrate how multiple biochemical processes can be exploited to impair bacterial cell wall formation.

Despite their therapeutic importance, cell wall inhibitors face increasing resistance from bacterial pathogens. One prominent mechanism involves the production of beta-lactamases, enzymes that hydrolyze the characteristic beta-lactam ring of penicillins, cephalosporins, and related agents. Ring hydrolysis alters the antibiotic’s chemical structure and abolishes or substantially reduces its ability to inhibit susceptible PBPs. In penicillin degradation, this reaction can produce penicilloic acid, which lacks the characteristic antibacterial activity of the intact drug.

Extended-spectrum beta-lactamases (ESBLs) can inactivate many penicillins and cephalosporins, including extended-spectrum agents, thereby limiting treatment options for infections caused by resistant organisms. Bacteria may also resist beta-lactams through altered PBPs with reduced antibiotic affinity, as exemplified by the modified PBP2a associated with methicillin resistance in Staphylococcus aureus. Gram-negative bacteria can further reduce antibiotic susceptibility through decreased outer-membrane permeability and increased efflux activity. Some organisms combine these mechanisms, producing clinically significant multidrug resistance.

Inhibition of DNA synthesis in bacteria

Deoxyribonucleic acid (DNA) is the fundamental genetic material of bacterial cells, carrying the hereditary information required for cellular growth, metabolism, reproduction, and survival. The integrity and continuous replication of bacterial DNA are essential for the maintenance of cellular functions and the propagation of genetic information to daughter cells. Antibiotics that interfere with bacterial DNA synthesis or associated genetic processes therefore represent an important group of antibacterial agents.

Antibacterial agents interfere with bacterial genetic processes through several distinct biochemical pathways. Fluoroquinolones for example, disrupt DNA replication and chromosome maintenance, sulfonamides and trimethoprim restrict nucleotide production through folate pathway inhibition, and rifampicin blocks RNA transcription. Their activity is mediated through the disruption of specific molecular targets involved in DNA replication, nucleotide production, and, in some cases, transcription.

By interfering with these essential processes, such agents can inhibit bacterial multiplication or cause irreversible cellular damage, depending on the drug, bacterial species, and concentration achieved at the site of infection. One major mechanism involves the inhibition of bacterial DNA gyrase and topoisomerase IV, enzymes that regulate DNA topology during replication and chromosome separation. DNA gyrase, also known as topoisomerase II, introduces negative supercoils into bacterial DNA, thereby reducing the torsional stress generated as the replication machinery moves along the chromosome.

Topoisomerase IV contributes to the separation of interlinked daughter chromosomes following DNA replication. Fluoroquinolones, including ciprofloxacin and levofloxacin, inhibit these enzymes by stabilising enzyme–DNA cleavage complexes. This action prevents the normal rejoining of DNA strands, leading to DNA breaks, impaired chromosome replication, and bacterial cell death. The effectiveness of these agents depends on the susceptibility of the organism and the accessibility of the drugs to their intracellular targets.

A different approach to disrupting bacterial DNA production involves the inhibition of nucleotide biosynthesis. Sulfonamides, such as sulfamethoxazole, are structural analogues of para-aminobenzoic acid (PABA) and competitively inhibit dihydropteroate synthase, an enzyme involved in bacterial folate synthesis. Folate derivatives are required for the production of purines and thymidylate, which are essential precursors for DNA formation.

By restricting folate availability, sulfonamides reduce the bacterial capacity to synthesise nucleotides and consequently impair DNA replication. Trimethoprim acts at a subsequent stage of the same metabolic pathway by inhibiting bacterial dihydrofolate reductase. This enzyme converts dihydrofolate into tetrahydrofolate, a cofactor required for nucleotide synthesis. The combined use of sulfamethoxazole and trimethoprim produces sequential blockade of folate metabolism, enhancing antibacterial activity against susceptible organisms.

It is important to distinguish inhibition of DNA replication from inhibition of transcription. Rifampicin primarily interferes with RNA synthesis rather than directly inhibiting DNA synthesis. It binds to the β-subunit of bacterial DNA-dependent RNA polymerase, preventing the initiation of RNA transcription. This interruption limits the production of messenger RNA and other essential RNA molecules, thereby disrupting protein expression and bacterial viability. Although transcription inhibition affects the expression of genetic information, it represents a distinct mechanism from the direct inhibition of DNA replication.

The clinical and microbiological significance of these mechanisms is influenced by bacterial resistance. Mutations in DNA gyrase or topoisomerase IV can reduce fluoroquinolone binding, while alterations in drug permeability and increased efflux activity can lower intracellular antibiotic concentrations. Resistance to sulfonamides and trimethoprim may arise through altered target enzymes, acquisition of resistant enzyme variants, or increased production of relevant metabolic substrates. These adaptations can diminish treatment effectiveness and highlight the importance of susceptibility testing and appropriate antimicrobial selection.

Destruction of bacterial cell membrane

The microbial cell membrane is an essential biological structure responsible for maintaining cellular integrity, regulating the movement of substances, generating energy, and supporting numerous metabolic processes. In bacteria, the cytoplasmic membrane functions as a selectively permeable barrier that separates the intracellular environment from the external surroundings. Its structural organization enables bacteria to maintain ionic gradients, transport nutrients, eliminate metabolic waste, and sustain the physiological conditions required for survival. Disruption of membrane integrity represents an effective mechanism through which antimicrobial agents inhibit bacterial growth or induce cell death.

Bacterial cytoplasmic membranes consist primarily of phospholipids and proteins arranged in a dynamic bilayer. Unlike the plasma membranes of most mammalian cells, bacterial membranes generally lack sterols, although exceptions exist, including certain sterol-containing bacteria and organisms that incorporate sterol-like molecules. This structural distinction contributes to the selective activity of particular membrane-targeting agents. However, the absence of sterols alone does not explain the selectivity of all antibacterial drugs, because membrane composition, surface charge, permeability, and the presence of specialized envelope structures also influence antimicrobial susceptibility.

Membrane-disrupting antibiotics act through different molecular interactions depending on their chemical structure and target. Some compounds bind to membrane phospholipids, whereas others interact with specific lipid components or alter membrane organization. These interactions may increase membrane permeability, disturb lipid packing, and compromise the barrier that normally prevents uncontrolled movement of ions and intracellular substances. The resulting physiological disturbances can rapidly undermine bacterial viability.

One important consequence of membrane disruption is the loss of essential intracellular constituents. When the membrane becomes excessively permeable, potassium ions, metabolites, and other small molecules may escape from the cytoplasm, disturbing osmotic balance and intracellular homeostasis. Severe damage can also interfere with membrane-associated enzymes, nutrient transport systems, and the maintenance of proton motive force. This electrochemical gradient is particularly important for ATP generation, active transport, and other energy-dependent cellular functions.

As membrane damage progresses, bacteria may become unable to maintain their normal metabolic activities. Disruption of ion gradients can reduce energy production, impair the uptake of essential nutrients, and interfere with biosynthetic reactions. Depending on the antimicrobial agent, concentration, bacterial species, and physiological conditions, these effects may result in growth inhibition, irreversible cellular injury, or bacterial death.

Polymyxins, including polymyxin B and colistin (polymyxin E), are important examples of membrane-active antibacterial agents. They are particularly active against susceptible Gram-negative bacteria because they interact with lipopolysaccharide (LPS) and phospholipids in the outer membrane. Their positively charged regions bind to negatively charged components of the bacterial surface, while their hydrophobic regions contribute to interactions with membrane lipids. These interactions destabilize the outer membrane and facilitate subsequent damage to the cytoplasmic membrane.

The resulting loss of envelope integrity disrupts essential cellular functions and can lead to bacterial death. Nevertheless, polymyxin activity varies among bacterial species, and resistance may develop through modifications of lipid A that reduce the affinity of these agents for the bacterial surface. Polymyxins also have clinically significant toxicity, particularly nephrotoxicity, which limits their use and requires careful therapeutic consideration.

Polyenes, such as amphotericin B and nystatin, provide a related but mechanistically distinct example of membrane-targeting antimicrobial agents. These compounds bind preferentially to ergosterol, a major sterol in fungal cell membranes, disrupting membrane organization and permeability. Their primary clinical application is antifungal rather than antibacterial therapy. Therefore, polyenes should not be classified as conventional antibacterial antibiotics, even though they illustrate how selective interactions with membrane lipids can compromise microbial cell integrity.

Inhibition of protein synthesis by antibacterial agents

Protein synthesis is an essential biological process through which bacterial cells produce the enzymes, structural proteins, transport molecules, and regulatory factors required for growth, metabolism, replication, and survival. Inhibition of this process represents a major mechanism of antibacterial action because it interferes with the ability of bacteria to translate genetic information into functional proteins. Bacterial ribosomes differ structurally from those of mammalian cells, providing an important basis for the selective activity of several antibacterial agents. Although both bacterial and eukaryotic ribosomes perform the same fundamental function, their differences in ribosomal RNA composition, protein organization, and antibiotic-binding sites enable certain drugs to preferentially inhibit bacterial translation.

Bacterial ribosomes are classified as 70S particles, consisting of two unequal subunits: the 30S small subunit and the 50S large subunit. The 30S subunit is primarily involved in decoding messenger RNA (mRNA) and ensuring the accurate incorporation of amino acids according to the genetic sequence. In contrast, the 50S subunit contains the peptidyl transferase centre, which catalyses peptide-bond formation during the elongation of the growing polypeptide chain. Together, these subunits coordinate translation through a series of molecular events, including initiation, aminoacyl-transfer RNA (tRNA) selection, peptide-bond formation, ribosomal translocation, and termination. Disruption of any of these stages can reduce protein production and compromise bacterial viability.

Protein synthesis-inhibiting antibiotics exert their effects by interacting with specific sites on either the 30S or 50S ribosomal subunit. These interactions interfere with distinct stages of translation rather than acting through a single universal mechanism. For example, tetracyclines bind reversibly to the 30S subunit and prevent aminoacyl-tRNA from accessing the A site of the ribosome. The addition of new amino acids to the developing polypeptide chain is restricted, resulting in predominantly bacteriostatic activity. Streptomycin, an aminoglycoside, also targets the 30S subunit but disrupts accurate decoding of mRNA and promotes the incorporation of incorrect amino acids. This mistranslation produces abnormal proteins and may contribute to bacterial cell damage and death.

Antibacterial agents directed against the 50S subunit interfere with other critical events in translation. Chloramphenicol inhibits the peptidyl transferase activity of the ribosome, thereby suppressing peptide-bond formation and preventing effective polypeptide elongation. Macrolides, including erythromycin and azithromycin, bind to the 50S subunit and interfere with elongation and movement of the nascent peptide through the ribosomal exit tunnel. Depending on the drug, bacterial species, and concentration, these effects can impede translation and produce bacteriostatic activity. Other agents, such as linezolid, inhibit the formation of the functional initiation complex, demonstrating that ribosomal inhibition can occur at different stages of protein production.

The antibacterial selectivity of these compounds arises primarily from differences between bacterial ribosomes and eukaryotic cytoplasmic ribosomes. Nevertheless, selectivity is not absolute, and some antibiotics may affect mitochondrial protein synthesis because mitochondria retain bacterial-like translational machinery. Adverse effects therefore depend on the drug’s pharmacological properties, dose, tissue distribution, and duration of exposure.

Bacteria may also develop resistance through several mechanisms, including modification of ribosomal binding sites, enzymatic inactivation of antibiotics, reduced intracellular drug accumulation, and active efflux. These adaptations can diminish drug–target interactions and reduce treatment effectiveness. Inhibition of bacterial protein synthesis involves multiple molecular targets within the translation machinery. By selectively disrupting ribosomal function, tetracyclines, streptomycin, chloramphenicol, macrolides, and related agents restrict bacterial growth or promote bacterial killing, depending on their mechanism of action and the susceptibility of the organism.

Inhibition of metabolic pathways by antibacterial agents

The inhibition of metabolic pathways is an important mechanism of action of antibacterial agents. It involves the selective interruption of essential biochemical reactions required for microbial growth, survival, and reproduction. A major example is the inhibition of folate biosynthesis, a metabolic process necessary for producing nucleotides and other cellular components. Antibacterial agents that interfere with these biochemical reactions are commonly described as antimetabolites because they mimic natural metabolic substrates or inhibit enzymes involved in essential metabolic processes. Important examples include sulphonamides and trimethoprim, while pyrimethamine primarily targets folate metabolism in protozoan parasites.

Folate, also known as vitamin B9, functions as a coenzyme in several metabolic reactions, particularly those involved in the synthesis of purines and thymidylate. These compounds are essential building blocks of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Consequently, an adequate supply of folate-derived cofactors is necessary for nucleic acid synthesis, cell division, and microbial multiplication. Interference with folate metabolism therefore restricts the production of genetic material and can prevent microorganisms from growing and reproducing effectively.

Unlike humans and many other mammals, which obtain folate primarily from dietary sources, most bacteria synthesize folate through their own metabolic pathways. This difference provides a useful target for selective antimicrobial therapy because certain drugs can inhibit microbial folate production without directly blocking the equivalent pathway in human cells. Sulphonamides are structural analogues of para-aminobenzoic acid (PABA), a substrate required for bacterial folate biosynthesis. Under normal conditions, the enzyme dihydropteroate synthase catalyses the incorporation of PABA into a pteridine-derived intermediate, producing dihydropteroic acid, which is subsequently converted through several reactions into dihydrofolate and tetrahydrofolate.

Because sulphonamides resemble PABA structurally, they compete with it for the active site of dihydropteroate synthase. This competitive inhibition interferes with the formation of dihydropteroic acid and reduces the availability of folate derivatives required for nucleotide biosynthesis. As the supply of purines and thymidylate becomes insufficient, DNA replication and cell division are impaired. Sulphonamides are generally bacteriostatic, meaning that they inhibit bacterial growth rather than directly killing bacteria under typical conditions.

Examples include sulfamethoxazole, sulfadiazine, and sulfisoxazole. Sulfamethoxazole is frequently administered in combination with trimethoprim to produce a sequential blockade of folate metabolism. Trimethoprim acts at a different stage of the same metabolic pathway. It selectively inhibits bacterial dihydrofolate reductase, the enzyme responsible for converting dihydrofolate into tetrahydrofolate. Tetrahydrofolate supplies one-carbon units needed for the synthesis of purines and thymidylate. Its depletion therefore disrupts DNA synthesis and limits bacterial multiplication.

When trimethoprim is combined with sulfamethoxazole, the two agents inhibit successive steps in folate metabolism. Sulfamethoxazole reduces folate precursor formation, while trimethoprim restricts the production of biologically active tetrahydrofolate. This sequential inhibition can produce a stronger antibacterial effect than either drug alone against susceptible organisms. The therapeutic value of this mechanism lies in its ability to exploit biochemical differences between microorganisms and human cells. Nevertheless, resistance can develop through altered target enzymes, increased PABA production, reduced drug uptake, or enhanced drug efflux.

These adaptations may decrease antimicrobial effectiveness and influence treatment selection. Metabolic pathway inhibition deprives susceptible microorganisms of essential biochemical intermediates. By disrupting folate biosynthesis and nucleotide production, sulphonamides and trimethoprim interfere with DNA replication, cell division, and microbial proliferation. This mechanism remains an important principle in antimicrobial pharmacology and illustrates how selective interference with microbial metabolism can be used to control bacterial infections.

References

Ashutosh Kar (2008). Pharmaceutical Microbiology, 1^st edition. New Age International Publishers: New Delhi, India. 

Denyer S.P., Hodges N.A and Gorman S.P (2004). Pharmaceutical Microbiology. 7^th ed. Blackwell Publishing Company, USA.

Fernandes Prabhavathi (2006). Antibacterial discovery – the failure of success? Nature Biotechnology, 24(12):1.

Finch R.G, Greenwood D, Norrby R and Whitley R (2002). Antibiotic and chemotherapy, 8^th edition. Churchill Livingstone, London and Edinburg.

Mazel D and Davies J (1998). Antibiotic Resistance: The Big Picture. In B. Rosen and S. Mobashery (Eds). Resolving the antibiotic paradox: progress in understanding drug resistance and developments of new antibiotics. New York: Plenum Press.

Russell A.D and Chopra I (1996). Understanding antibacterial action and resistance. 2^nd edition. Ellis Horwood Publishers, New York, USA.

Ma, H., Zhang, L., Wang, L., Yang, Z., Liu, J., Sun, H., Ge, S., & Quan, C. (2026). Antibiotic Mechanisms and Resistance: Molecular Insights and Therapeutic Strategies. Antibiotics, 15(4), 351.

Halawa EM, Fadel M, Al-Rabia MW, Behairy A, Nouh NA, Abdo M, Olga R, Fericean L, Atwa AM, El-Nablaway M and Abdeen A (2024) Antibiotic action and resistance: updated review of mechanisms, spread, influencing factors, and alternative approaches for combating resistance. Front. Pharmacol. 14:1305294.